• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

High-capacity nanoparticle holds potential for targeted cancer therapies

September 15, 2016 By Sarah Faulkner

High-capacity nanoparticle holds potential for targeted cancer therapies
Image: Jeremiah Johnson

Chemists from the Mass. Institute of Technology developed a nanoparticle that they can pack with 3 or more drugs to create custom combination therapies for cancer, according to a study published this week in the Journal of the American Chemical Society.

The team also revealed that cisplatin, a powerful anti-cancer drug, doesn’t work using the same DNA-damaging mechanism when delivered via nanoparticle compared to traditional methods.

The team uses a unique nanoparticle production method, which they 1st reported in 2014. Instead of trying to load the drugs onto nanoparticles that are already built, they create the nanoparticles from building blocks already containing the drugs. This gives them more precise control over the structure of the nanoparticle and the dosage of each drug, they argue.

“We can take any drug, as long as it has a functional group [a group of atoms that allows a molecule to participate in chemical reactions], and we can load it into our particles in exactly the ratio that we want, and have it release under exactly the conditions that we want it to,” senior author Jeremiah Johnson explained to MIT News. “It’s very modular.”

The researchers delivered doses of 3 different cancer-fighting drugs – cisplatin, doxorubicin and camptothecin – to mice and observed that ovarian tumors shrank among mice that received treatment. The team also found that survival rates were higher for treated mice than untreated mice, with fewer side effects.

To understand how the nanoparticles affected the cells, the team measured the more than 100 genes involved in the programmed cell death triggered by cancer drugs. Camptothecin and doxorubicin destroyed DNA using their usual pathways, but cisplatin exhibited a mechanism characterized by a different cancer drug, known as oxaliplatin.

Johnson suggested that this could be a more widespread problem than once thought, since many research teams attach cisplatin to nanoparticles in the same way.

Johnson’s lab is working on a nanoparticle that uses cisplatin’s usual mechanism, as well as high-capacity nanoparticles with a drug combination for pancreatic cancer.

Filed Under: Drug-Device Combinations, Oncology, Research & Development Tagged With: Mass. Institute of Technology

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS